Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal

Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and commercialize the DLL3 group of cell therapies.